Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clinical Trial Expertise Key To Early-Stage Company Deals – Medtronic COO

This article was originally published in The Gray Sheet

Executive Summary

Clinical data quality and integrity should be the main consideration for manufacturers evaluating a merger or alliance with an early-stage technology developer, according to Medtronic COO Bill Hawkins

You may also be interested in...



Device Firms Will Collaborate With Pharma, Rather Than Merge – Hawkins

Mergers of drug discovery companies with device developers will remain rare, even as collaborations across the drug, device and biologics industries become more common, Medtronic COO Bill Hawkins maintains

Cardiac Monitor Maker Courts Payment Latitude Prior To Home-Use Launch

Guidant says it will release a home-use version of its Latitude advanced patient management (APM) system upon gaining a CPT code to drive reimbursement

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel